← Back to headlines
Biogen and Denali Discontinue Parkinson's Therapy After Trial Setback
Biogen and Denali Therapeutics have announced they will discontinue their Parkinson's disease therapy after it failed to meet expectations in a mid-stage clinical trial.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
